Recently, it has been reported that combination of BIRC5 inhibitor with osimertinib can effectively inhibit the growth of lung cancer in mouse xenograft model (48), and a phase II clinical trial showed YM155 exhibited modest single-agent activity in patients with refractory in advanced NSCLC (49), indicating that BIRC5 may be a new target to overcome TKI resistance in LUAD. The gene discussed is BIRC5; the disease is lung carcinoma.